The Recall Desk
SevereFDA (Drugs)·D-0368-2019·Announced 2019-01-23

Aurobindo Recalls Valsartan and Hydrochlorothiazide Tablets Due to NDEA Impurity

Aurobindo Pharma USA Inc. is recalling specific lots of Valsartan and Hydrochlorothiazide tablets because FDA testing found the impurity NDEA above acceptable levels.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classification is FDA Class II, and the presence of NDEA, a probable human carcinogen, above acceptable limits constitutes a significant health risk, aligning with the 'Severe' criteria for significant injury/property-damage reports or high-risk contamination.

Plain-English summary

Aurobindo Pharma USA Inc. is recalling 32,160 bottles of Valsartan and Hydrochlorothiazide tablets USP 80 mg/12.5 mg, 90-count. The affected lots are HVSA17011-A (exp. 11/2020), HVSA17012-A (exp. 11/2020), and HVSA18001-A (exp. 12/2020). The product was distributed to 25 distributors and retail chains who may have further distributed it throughout the United States.

The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. FDA laboratory testing confirmed the presence of the impurity N-nitrosodimethylamine (NDEA) in the active pharmaceutical ingredient (API) used to manufacture the product. The levels of NDEA were found to be above the interim acceptable daily intake level of 0.083 parts per million.

Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed above. If the product matches the recalled description, it should be returned to the pharmacy or distributor for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if they have been taking the affected medication.

The recalled product

Product
VALSARTAN AND HYDROCHLOROTHIAZIDE (VALSARTAN AND HYDROCHLOROTHIAZIDE)
Brand
VALSARTAN AND HYDROCHLOROTHIAZIDE
Manufacturer
Aurobindo Pharma USA Inc.
Category
Drug — Prescription Medication
Hazard
Affected units
32,160

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot # HVSA17011-A
  • exp. date 11/2020 Lot # HVSA17012-A
  • exp. date 11/2020 Lot # HVSA18001-A
  • exp. date 12/2020

Distribution

Distribution scope not specified by the agency.

Part of a larger recall action

This product is one of 10 recalled by Aurobindo Pharma USA Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 10 products in this recall →

Related recalls

Same brand · VALSARTAN AND HYDROCHLOROTHIAZIDE

Same manufacturer · Aurobindo Pharma USA Inc.

See all →

Same hazard · nde contamination

See all →